Wall Street analysts predict that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will announce earnings per share of ($0.22) for the current quarter, Zacks reports. Three analysts have provided estimates for Ironwood Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.17) and the lowest estimate coming in at ($0.28). Ironwood Pharmaceuticals posted earnings of ($0.12) per share during the same quarter last year, which would indicate a negative year over year growth rate of 83.3%. The company is expected to announce its next earnings results on Tuesday, February 20th.
On average, analysts expect that Ironwood Pharmaceuticals will report full year earnings of ($1.12) per share for the current fiscal year, with EPS estimates ranging from ($1.19) to ($1.05). For the next financial year, analysts forecast that the firm will report earnings of ($0.57) per share, with EPS estimates ranging from ($0.80) to ($0.32). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.07. The business had revenue of $86.80 million during the quarter, compared to the consensus estimate of $73.59 million. Ironwood Pharmaceuticals had a negative net margin of 48.89% and a negative return on equity of 645.22%. The company’s quarterly revenue was up 31.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.18) earnings per share.
A number of equities research analysts have recently commented on IRWD shares. Credit Suisse Group started coverage on shares of Ironwood Pharmaceuticals in a report on Monday, November 27th. They set a “buy” rating and a $19.00 price target for the company. ValuEngine downgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. Mizuho downgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $20.00 to $16.00 in a report on Wednesday, December 6th. Morgan Stanley reiterated a “hold” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 4th. Finally, BidaskClub downgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, December 30th. Four equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $17.56.
In related news, CEO Peter M. Hecht sold 113,405 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $15.12, for a total value of $1,714,683.60. Following the sale, the chief executive officer now directly owns 4,696,917 shares of the company’s stock, valued at $71,017,385.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 115,769 shares of company stock worth $1,752,491 over the last three months. Corporate insiders own 7.63% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Gerber Kawasaki Wealth & Investment Management acquired a new stake in shares of Ironwood Pharmaceuticals in the third quarter worth approximately $170,000. Ameritas Investment Partners Inc. boosted its position in shares of Ironwood Pharmaceuticals by 5.8% in the second quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock worth $223,000 after acquiring an additional 648 shares during the last quarter. Virtu KCG Holdings LLC boosted its position in shares of Ironwood Pharmaceuticals by 10.3% in the second quarter. Virtu KCG Holdings LLC now owns 15,740 shares of the biotechnology company’s stock worth $297,000 after acquiring an additional 1,470 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Ironwood Pharmaceuticals by 554.4% in the second quarter. BNP Paribas Arbitrage SA now owns 17,046 shares of the biotechnology company’s stock worth $322,000 after acquiring an additional 14,441 shares during the last quarter. Finally, Amalgamated Bank boosted its position in shares of Ironwood Pharmaceuticals by 9.0% in the second quarter. Amalgamated Bank now owns 17,280 shares of the biotechnology company’s stock worth $326,000 after acquiring an additional 1,421 shares during the last quarter.
Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) traded down $0.32 during midday trading on Wednesday, hitting $13.85. 1,591,700 shares of the stock were exchanged, compared to its average volume of 1,598,971. The stock has a market capitalization of $2,080.00, a P/E ratio of -14.43 and a beta of 1.45. Ironwood Pharmaceuticals has a 1-year low of $13.43 and a 1-year high of $19.94. The company has a current ratio of 4.87, a quick ratio of 4.86 and a debt-to-equity ratio of -22.31.
COPYRIGHT VIOLATION WARNING: “Ironwood Pharmaceuticals, Inc. (IRWD) Expected to Post Earnings of -$0.22 Per Share” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/01/17/ironwood-pharmaceuticals-inc-irwd-expected-to-post-earnings-of-0-22-per-share.html.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Get a free copy of the Zacks research report on Ironwood Pharmaceuticals (IRWD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.